Table 1.
Characteristics of study participants at study visits
| Visit 1 (n=390) | Visit 2 (n=280) | Visit 3 (n=298) | |
|---|---|---|---|
|
| |||
| Age | 65.3 (10.3) | 67.1 (10.1) | 68.2 (9.5) |
| Male (vs female) | 54.1% | 53.2% | 52.3% |
| BMI | 27.3 (5.2) | 27.3 (5.1) | 27.3 (5.1) |
| Caucasian (vs non-Caucasian) | 97.4% | 97.1% | 98.0% |
| Comorbiditiesa | |||
| 0 comorbidities | 59.2% | 53.2% | 54.4% |
| 1 comorbidity | 32.3% | 33.6% | 26.8% |
| ≥2 comorbidities | 8.5% | 13.2% | 18.8% |
| Anxiety/depression (vs no) | 19.5% | 21.8% | 20.8% |
| Smoking between visits (vs no) | 76.2% | 29.3% | 26.5% |
| Lifetime pack-years smoked | 28.0 (26.5) | 26.6 (25.5) | 27.3 (25.4) |
| Any exacerbationsb (vs no) | 7.9% | 11.1% | 15.4% |
| MPRc | 79.9% (108.4) | 81.5% (112.4) | 79.3% (110.3) |
| FEV1 (L) | 2.1 (0.8) | 2.1 (0.8) | 2.1 (0.7) |
| % Predicted FEV1 | 74.4 (18.1) | 74.9 (19.1) | 75.7 (18.8) |
| Diagnosed COPD (vs undiagnosed) | 24.6% | 28.9% | 32.2% |
| Asthma (vs no) | 20.8% | 27.1% | 29.9% |
| Symptoms (present vs absent) | |||
| Cough | 47.7% | 47.1% | 40.6% |
| Phlegm | 33.8% | 31.8% | 28.2% |
| Wheeze | 51.3% | 43.6% | 42.6% |
| Dyspnead | 53.3% | 46.5% | 44.8% |
| Any symptomsd | 83.9% | 77.2% | 74.6% |
Notes: Means (and SDs) are reported unless otherwise indicated.
a
Participants reported whether they had ever been diagnosed with coronary artery disease, hypertension, diabetes, lung cancer, stroke, and tuberculosis at each study visit.
b
COPD exacerbations of any severity (mild, moderate, severe)2 over the past 12 months.
c
12-month medication possession ratio23 for all respiratory-related medications.
d
Determined for the subset of participants in which dyspnea was measured (N=415).
Abbreviations: BMI, body mass index; MPR, medication possession ratio.